The Illumina DRAGEN v4.5 software has been released with expanded capabilities to support genomic and multiomic analysis, improving accuracy and enabling deeper insights across rare disease and oncology research.
Illumina DRAGEN v4.5 enhances genomic analysis
Illumina confirmed that DRAGEN v4.5 introduces new analytical features designed to address complex genomic regions and challenging sample types.
The update includes support for the TruPath Genome and 5-base assays, extending the software’s application across germline, oncology and multiomic workflows.
Machine learning and pangenome advances improve accuracy
The latest version incorporates machine learning to enhance variant detection, particularly in difficult samples such as formalin-fixed paraffin-embedded tissues. According to Illumina, the update reduces false positives while maintaining sensitivity.
In addition, expanded pangenome representation aims to improve mapping accuracy across diverse populations, helping to reduce ancestry-related bias in genomic analysis.
Multiomic capabilities expand research applications
DRAGEN v4.5 introduces new structural variant calling and improved methylation analysis through Illumina’s 5-base solution, supporting integrated genetic and epigenetic research.
These capabilities enable researchers to explore more complex biological signals, particularly in areas such as cancer research and rare disease investigation.
New tools support oncology and biomarker discovery
The software also includes enhanced oncology features, including oncovirus detection and improved somatic variant analysis. These tools are designed to support the identification of biomarkers and improve understanding of disease mechanisms.
Further information is available on the Illumina website. Related coverage can be found in the Biotechnology section.
